



[Claremont BioSolutions]

ClaremontBio is selected by NIH to receive Technology Niche Analysis

Press Release No: 57

Contact: John Maveety- (909) 706- 2921

jmaveety@claremontbiosolutions.com

Upland, CA- October 1, 2009 - The National Institute of Health (NIH) has recognized ClaremontBio as one of only fifty 2009 NIH SBIR (Small Business Innovation Research) awardees to receive a supplemental award of having a Technology Niche Analysis (TNA™) performed by Foresight Science & Technology on the core technology developed in the SBIR. ClaremontBio's eligible NIH Phase 1 SBIR project is entitled "A fully integrated assay and platform for detecting *Clostridium difficile*."

The core sample preparation technology to be utilized in the SBIR project represents a major step towards the commercialization of novel, next-generation nucleic acid purification kits. As part of the SBIR, ClaremontBio will be working on developing an easy-to-use combination sample preparation and assay system for the rapid detection of *Clostridium difficile*. A point-of-care (POC) device will be developed that will rapidly extract DNA from clinical samples and environmental swabs using a simple 2-step process in order to rapidly detect the presence of pathogenic organisms.

NIH has contracted with Foresight Science & Technology provides businesses with a detailed Technology Niche Analysis (TNA™) report. The report will assess potential uses of the technology, as well as address the end-user needs, current and emerging competing technologies, the market dynamics, and the technology's competitive advantage. The program is aimed at helping SBIR Phase 1 awardees place their products into the marketplace by indentifying any additional niches, potential markets, and strategic alliances for the awardees' technology. The technology analysis for ClaremontBio will be focused on their novel PureLyse™ DNA Extraction technology, a critical stand-alone subcomponent of the integrated cartridge that is currently in beta testing under the SBIR. PureLyse™ consists of a miniature, disposable, low-power device, which is capable of rapidly performing both cell disruption and DNA extraction without the need for harsh reagents or multiple wash steps. The niche assessment is expected to substantiate the need and potential for micro-scale mechanical devices which can lyse cells and extract nucleic acid in 2 simple steps.

"...The market size for DNA extraction kits is so large, Claremont BioSolutions LLC may be able to accumulate significant revenue." –*Darice Bernier, Foresight Science & Technology.*

For Information: John Maveety, (909) 706- 2921

jmaveety@claremontbiosolutions.com

1182 Monte Vista Ave. Ste. # 11

Upland, CA 91786